Lung Cancer Clinical Trials & Research at Providence Medical Group

The two main types of lung cancer are non-small cell lung cancer and small cell lung cancer. The types are based on the way the cells look under a microscope. Non-small cell lung cancer is much more common than small cell lung cancer. Tobacco smoking is the most common cause of lung cancer.

Providence Medical Group is currently enrolling patients for the following lung cancer clinical trials:

Durvalumab vs Placebo With Stereotactic Body Radiation Therapy in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients / Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation (PACIFIC-4)

Treatment agent: Durvalumab vs Placebo vs Osimertinib +/- Radiotherapy
Physician: Michael N. Corradetti
Study Coordinator: Beatrice Becker // beatrice.becker@providence.org // 707-932-5164
Study Resources: https://clinicaltrials.gov/study/NCT03833154
Sponsor: AstraZeneca
Location: Providence Queen of the Valley Medical Center, Napa, CA

Study of Serplulimab plus chemotherapy in comparison with Atezolizumab plus chemotherapy in previously untreated US patients with Extensive stage small cell lung cancer. Astride: HLX10-005 SCLC301-E

Treatment agent: Recombinant anti-PD-1 humanized monoclonal antibody injection.
Physician: Ian Anderson, MD
Study Coordinator: Tracy Foster // tracy.foster@stjoe.org // 707-521-3830
Study Resources: To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC - Full Text View - ClinicalTrials.gov
Sponsor: Sermonix
Location: Providence Cancer Center Santa Rosa, CA

A study for patients with EGFR mutant advanced or metastatic non squamous non small cell lung cancer who have failed a EGFR-TKI treatment: HARMONi AK112-301

Treatment agent: Ivonescimab (SMT112 or AK112) Injection
Physician: Ian Anderson, MD
Study Coordinator: Tracy Foster // tracy.foster@stjoe.org // 707-521-3830
Study Resources: Phase 3 Clinical Study of AK112 for NSCLC Patients - Full Text View - ClinicalTrials.gov
Sponsor: Summit Therapeutics
Location: Providence Cancer Center Santa Rosa, CA

A study for patients with non small cell lung cancer with c-Met Exon 14 skip mutations and c-Met dysregulation advanced solid tumors

Treatment agent: APL-101 oral capsule
Physician: Ian Anderson, MD
Study Coordinator: Tracy Foster // tracy.foster@stjoe.org // 707-521-3830
Study Resources: https://classic.clinicaltrials.gov/ct2/show/NCT03175224
Sponsor: Apollomics Inc.
Location: Providence Cancer Center Santa Rosa, CA

A study for patients with Stage II-IIIB EFGR+ non small cell lung cancer who have had a resection with or without adjuvant chemotherapy: AZ D5162C000048 (TARGET)

Treatment agent: Osimertnib
Physician: Ian Anderson, MD
Study Coordinator: Tracy Foster // tracy.foster@stjoe.org // 707-521-3830
Study Resources: A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC) - Full Text View - ClinicalTrials.gov
Sponsor: AstraZeneca
Location: Providence Cancer Center Santa Rosa, CA

A study for patients with stage II-IIIA resectable EGFR+ non small cell lung cancer before surgery

Treatment agent: Osimertnib as monotherapy or in combination with chemotherapy vs standard of care alone
Physician: Ian Anderson, MD
Study Coordinator: Tracy Foster // tracy.foster@stjoe.org // 707-521-3830
Study Resources: A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer - Full Text View - ClinicalTrials.gov
Sponsor: AstraZeneca
Location: Providence Cancer Center Santa Rosa, CA

A study for patients with unresectable Stage IIIB non small cell lung cancer after chemotherapy and radiation: AZ D9075C00001- PACIFIC 8

Treatment agent: Durvalumab
Physician: Ian Anderson, MD
Study Coordinator: Tracy Foster // tracy.foster@stjoe.org // 707-521-3830
Study Resources: A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC - Full Text View - ClinicalTrials.gov
Sponsor: AstraZeneca
Location: Providence Cancer Center Santa Rosa, CA

A study for patients with Stage IV non small cell lung cancer with HER2 mutations in exons 19 or 20: AZ D9675SC00001 Destiny Lung 04

Treatment agent: Trastusumab deruxtecan (T-DXd)
Physician: Ian Anderson, MD
Study Coordinator: Tracy Foster // tracy.foster@stjoe.org // 707-521-3830
Study Resources: A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations - Full Text View - ClinicalTrials.gov
Sponsor: AstraZeneca
Location: Providence Cancer Center Santa Rosa, CA

A study for patients with Stage IV non small cell lung cancer after 1 line of treatment

Treatment agent: GEN1046 (biospecific antibody)
Physician: Ian Anderson, MD
Study Coordinator: Tracy Foster // tracy.foster@stjoe.org // 707-521-3830
Study Resources: Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer - Full Text View - ClinicalTrials.gov
Sponsor: Genmab
Location: Providence Cancer Center Santa Rosa, CA

A study for patients with metastatic non small cell lung cancer with a KRAS G12C mutation

Treatment agent: adagrasib
Physician: Ian Anderson, MD
Study Coordinator: Tracy Foster // tracy.foster@stjoe.org // 707-521-3830
Study Resources: Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21) - Full Text View - ClinicalTrials.gov
Sponsor: Mirati Therapeutics Inc.
Location: Providence Cancer Center Santa Rosa, CA

A study for patients with metastatic non small cell lung cancer with any KRAS mutation

Treatment agent: BBP-398, a SHP2 inhibitor, in combination with nivolumab, a PD-1 antibody.
Physician: Ian Anderson, MD
Study Coordinator: Tracy Foster // tracy.foster@stjoe.org // 707-521-3830
Study Resources: SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation - Full Text View - ClinicalTrials.gov
Sponsor: Navire Pharma Inc, a BridgeBio company
Location: Providence Cancer Center Santa Rosa, CA

Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-L1 Negative (Alliance A082002)

Treatment agent: Radiotherapy + Immunotherapy (+/- Chemotherapy)
Physician: Michael N. Corradetti
Study Coordinator: Beatrice Becker // beatrice.becker@providence.org // 707-932-5164
Study Resources: https://clinicaltrials.gov/study/NCT04929041
Sponsor: National Cancer Institute (NCI) / Alliance for Clinical Trials in Oncology
Location: Providence Queen of the Valley Medical Center, Napa, CA

A Randomized, Double-Blind, International Multicenter, Phase III Study to Evaluate the Anti-Tumor Efficacy and Safety of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) or Placebo in Combination with Chemotherapy (Carboplatin/Cisplatin-Etoposide) and Concurrent Radiotherapy in Patients with Limited-Stage Small Cell Lung Cancer (LS-SCLC) HLX10-020-SCLC302

Treatment agent: Serplulimab (HLX10) vs Placebo + Chemotherapy + Radiotherapy
Physician: Ian Anderson, MD
Study Coordinator: Tracy Foster // tracy.foster@stjoe.org // 707-521-3830
Study Resources: https://www.clinicaltrials.gov/study/NCT05353257
Sponsor: Shanghai Henlius Biotech
Location: Providence Cancer Center Santa Rosa, CA

A Randomized Prospective Trial of Adjuvant Chemotherapy in Patients with Completely Resected Stage I or IIA Non-Squamous Non-Small Cell Lung Cancer Identified as High or Intermediate Risk by a 14-Gene Prognostic Assay

Treatment agent: Adjuvant Chemotherapy + Radiographic surveillance + 14-Gene Prognostic Assay
Physician: Ian Anderson, MD
Study Coordinator: Melissa Ulrich // melissa.ulrich@providence.org // 707-521-3830
Study Resources: https://clinicaltrials.gov/study/NCT01817192
Sponsor: Razor Genomics
Location: Providence Cancer Center Santa Rosa, CA

A Phase 1 Study of the SHP2 Inhibitor BBP-398 in combination with the Programmed Death Receptor-1 Blocking Antibody Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer with a KRAS Mutation (NAV-1004)

Treatment agent: BBP-398 (oral medication) + Nivolumab
Physician: Ian Anderson, MD
Study Coordinator: Tracy Foster // tracy.foster@stjoe.org // 707-521-3830
Study Resources: https://clinicaltrials.gov/study/NCT05375084
Sponsor: Navire Pharma Inc.
Location: Providence Cancer Center Santa Rosa, CA